The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified genetic markers associated with this serious condition.

Neuropathic pain is a chronic and debilitating condition that impacts around 10% of the population in both the United States and Europe. Despite advances in understanding the mechanisms of neuropathic ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

“The formation of Dogwood Therapeutics last month represents a transformational expansion of our pipeline with the addition of Halneuron ®, a non-opioid, novel NaV 1.7 modulator to treat neuropathic ...

In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, shooting, tingling ice or stabbing sensation. Conditions such as diabetes or ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...